MacuSight Expands Management Team With Appointment of Dr. Joel Naor as Chief Medic...( UNION CITY Calif. Feb. 20 /- Macu...),Health
Navigation Links
MacuSight Expands Management Team With Appointment of Dr. Joel Naor as Chief Medical Officer
Date:2/20/2008
UNION CITY, Calif., Feb. 20 /PRNewswire/ -- MacuSight(TM), Inc., a developer of innovative therapeutics for the treatment of severe ocular diseases and conditions, today announced the appointment of Joel Naor, M.D., M.Sc., MBA, as the company's chief medical officer. With broad expertise in the clinical development of therapeutics for ocular diseases and conditions, Dr. Naor will play a key role in MacuSight's ongoing advancement of its sirolimus program, as well as the company's overall scientific direction. MacuSight is currently developing its proprietary sirolimus product for the treatment of wet age-related macular degeneration (wet AMD) and diabetic macular edema (DME), as well as various additional ocular diseases and conditions.
Formerly, as a senior medical director at Allergan, Inc., Dr. Naor was a key contributor to the medical and scientific direction of the company's two lead retina programs. In his role as the global project team leader for Allergan's POSURDEX(R) program, Dr. Naor oversaw a multifunctional team with responsibilities that spanned clinical development, regulatory, CMC and marketing. Most recently, he served on Allergan's global medical affairs group as a medical director, retina. Prior to his work with Allergen, Dr. Naor was a director of clinical research at QLT, Inc. where he served as a clinical lead on the global project team for Visudyne(R) (verteporfin for injection).
"Through his work at both Allergan and QLT, Joel has gained valuable
experience and strategic insight related to the successful advancement of
novel ocular therapeutics through clinical trials," stated David A. Weber,
Ph.D., president and chief executive officer of MacuSight. "It is this
expertise that makes him an ideal fit for MacuSight as we work to
aggressively and successfully advance our sirolimus program through
clinical development and toward the market. We are excited to have Joel as
part of the team and look forward to the key contributi
'/>"/>
| SOURCE MacuSight, Inc. Copyright©2008 PR Newswire. All rights reserved |
Related medicine news :
1. Veteran Bariatric Surgeon Expands Services to Solano County
2. Tahitian Noni International Expands HIRO(TM) Beverage Line With Super Fruits Sparkling Black Currant
3. Convera(R) Expands Advanstar OnLine Business to Vertical Search Covering Pharmaceutical Industry Applications
4. Hondros College Expands School of Nursing to Columbus and Dayton; Students Can Begin LPN Education Almost Immediately
5. Beryl Expands Leadership Team, Adds Senior VP of Product Management and Marketing
6. Anthem Blue Cross and Blue Shield Expands Network of Hospitals to Serve Hoosier Healthwise Members
7. Henry Ford Hospital expands research on gene and radiation therapy for prostate cancer
8. HearAtLast Expands Chain to 18 Locations Opening New Clinic in Aurora, Ontario Wal-Mart Store # 5778
9. HearAtLast Expands Chain to 17 Locations, Opening New Clinic in Oshawa, Ontario Wal-Mart Supercenter # 1056
10. Cell Therapeutics, Inc. (CTI) Cuts Net Operating Expenses 35% and Expands Commercial Team to Support Zevalin(R) Sales and Applications Seeking Two Product Approvals in 2009
11. SAFC Pharma Expands Its Pharmorphix Solid State Chemistry Services
Post Your Comments:
(Date:12/4/2009).... 4 , ,What: Humana ( ht... health benefits provider, is introd...s.com ), a senior-friendly dance pad, ...ues., Dec. 8 at 1 p.m. The festive ...n to the public, will feature Dancetown, ...
(Date:12/4/2009)...PRNewswire-FirstCall/ -- MedClean Technologies, In...Company has entered into a preferred stock purchas...ware limited liability company, doing business as... to the Purchase Agreement, MedClean will receive ...agreed to sell up to 750 shares of its Series C Pr...
(Date:12/4/2009)...Newswire/ -- PLUS Diagnostics announced today th...y services with the launch of a national hematolog... company,s expansion from a regional laboratory to...ering diagnostic services across a full range of s... now hematology/oncology. ,, PLUS Diagnostics ...
(Date:12/4/2009)...RNewswire-FirstCall/ -- PD-Rx Pharmaceuticals, Inc...5,012,334 for the first quarter ended September 30...ear. Operating income and net income for the quar...a 70% decrease over the same period last year. ,... sector sales. This trend is expected to continue...
(Date:12/4/2009)...swire/ -- The National Cancer Institute has awarde...Hutchinson Cancer Research Center to become the na...vice Contact Center. ,, The move will create 60...ng the size of its current CIS workforce - once th...is scheduled for March 15, 2010. The Seattle CIS c...
Breaking Medicine News(10 mins):Health News:Humana Launches Dancetown on Tues., Dec. 8 in Kissimmee 2Health News:MedClean Technologies Enters Into Preferred Stock Agreement of Up to $7.5 Million 2Health News:MedClean Technologies Enters Into Preferred Stock Agreement of Up to $7.5 Million 3Health News:PLUS Diagnostics Launches Hematology/Oncology Diagnostic Services 2Health News:PLUS Diagnostics Launches Hematology/Oncology Diagnostic Services 3Health News:PD-Rx Pharmaceuticals, Inc. Reports 1st Quarter Earnings 2Health News:Hutchinson Center Wins $55.4 Million Contract to Become Sole Operator of the NCI Cancer Information Service 2[0] Humana Launches Dancetown on Tues., Dec. 8 in Kissimmee[0] MedClean Technologies Enters Into Preferred Stock Agreement of Up to $7.5 Million[0] PLUS Diagnostics Launches Hematology/Oncology Diagnostic Services[0] PD-Rx Pharmaceuticals, Inc. Reports 1st Quarter Earnings[0] Hutchinson Center Wins $55.4 Million Contract to Become Sole Operator of the NCI Cancer Information Service
... Madhya Pradesh may raise the retirement age of me... doctors posted in interior areas// in order to pr...etter health and medical services to people is a p...ce will also be provided to them," Chief Minister ...
... Dubai: With a motive of enabling women the best p...s about to commence a free breast cancer screening...
The tests will enable all women in the emirate, U...ter treatment outcomes.
Dr Hajer Al Hosani,...
... AMA President, Dr Mukesh Haikerwal, said today th...rocesses for assessing the skills// and experience... confidence in the quality of medicine in Australi... and fair to ensure the community gets expert medi...
... American scientists have identified a single prot... the development of diabetes//.
Researchers at...calcineurin, is vital to the proper functioning of...0 genes that had already been linked to diabetes. ...
... According to a study conducted at the University ...evelopment of chronic pain following breast cancer...ve surgery, and severe post-operative pain.
...ths, near the breast, next to armpit and in the up...
... A team of scientists from Bristol University has ...e energy levels in living heart cells that will ai...rt attack.
The scientists expect this techni... Chemistry.
Dr Elinor Griffiths and her team...
Other Medicine News:Health News:Consistent National Standards For Assessment Of Overseas Trained Doctors A Priority 2Health News:Post-Operative Pain in Breast Cancer Surgery 2Health News:A glowing energy measure for heart cells 2Madhya Pradesh to Raise the Retirement Age of Specialist Medicos'Dubai to commence free breast cancer screeningConsistent National Standards For Assessment Of Overseas Trained Doctors A PriorityDiabetes Protein Identified by U.S. ScientistsPost-Operative Pain in Breast Cancer SurgeryA glowing energy measure for heart cells
(Date:12/3/2009)...c. 3 Radiology imaging leader MEDR...ration capabilities at the November 2009 Radiology...t.PACS(TM) product, enabling the first radiology ...t release in the company,s newly branded Certegra...://www.newscom.com/cgi-bin/prnh/20091203/NE20631 ...
(Date:12/3/2009).... 3 Wound Management...rapidly growing provider of specialty medical prod... Industry Representative Association (HIRA) to ser...ing representative to market the company,s core Ce...IRA will market and sell Wound Management Technolo...
(Date:12/3/2009)...re-FirstCall/ -- Cardium Therapeutics (NYSE Amex: ...diary, Tissue Repair Company, submitted a 510(k) p...d Drug Administration (FDA) seeking marketing clea...sed on positive data from the Company,s recently c...submission with the FDA covers Excellagen XL(TM) ...
Breaking Medicine Technology:MEDRAD Demonstrates PACS Injection-Record Integration at RSNA 2009 2MEDRAD Demonstrates PACS Injection-Record Integration at RSNA 2009 3Wound Management Technologies, Inc. Signs Agreement with Major Sales Representative Organization for Increased Marketing of CellerateRx(R); Third Quarter Sales Up 2Wound Management Technologies, Inc. Signs Agreement with Major Sales Representative Organization for Increased Marketing of CellerateRx(R); Third Quarter Sales Up 3Cardium Files FDA 510(k) Application for U.S. Marketing Clearance of ExcellagenXL(TM) Topical Gel and ExcellagenFX(TM) Flowable Collagen Protein-Based Matrix for Diabetic, Pressure and Venous Ulcers and Other Dermal Wounds 2Cardium Files FDA 510(k) Application for U.S. Marketing Clearance of ExcellagenXL(TM) Topical Gel and ExcellagenFX(TM) Flowable Collagen Protein-Based Matrix for Diabetic, Pressure and Venous Ulcers and Other Dermal Wounds 3Cardium Files FDA 510(k) Application for U.S. Marketing Clearance of ExcellagenXL(TM) Topical Gel and ExcellagenFX(TM) Flowable Collagen Protein-Based Matrix for Diabetic, Pressure and Venous Ulcers and Other Dermal Wounds 4Cardium Files FDA 510(k) Application for U.S. Marketing Clearance of ExcellagenXL(TM) Topical Gel and ExcellagenFX(TM) Flowable Collagen Protein-Based Matrix for Diabetic, Pressure and Venous Ulcers and Other Dermal Wounds 5Sigma Aldrich Acquires ChemNavigator Inc to Provide Researchers With Industry Leading Chemical Compound Selection and Procurement Services 13431 1Sigma Aldrich Acquires ChemNavigator Inc to Provide Researchers With Industry Leading Chemical Compound Selection and Procurement Services 13431 2Sigma Aldrich Acquires ChemNavigator Inc to Provide Researchers With Industry Leading Chemical Compound Selection and Procurement Services 13431 3SEQUENOM Reports Second Quarter 2009 Financial Results and Highlights 13427 1SEQUENOM Reports Second Quarter 2009 Financial Results and Highlights 13427 2SEQUENOM Reports Second Quarter 2009 Financial Results and Highlights 13427 3SEQUENOM Reports Second Quarter 2009 Financial Results and Highlights 13427 4SEQUENOM Reports Second Quarter 2009 Financial Results and Highlights 13427 5SEQUENOM Reports Second Quarter 2009 Financial Results and Highlights 13427 6SEQUENOM Reports Second Quarter 2009 Financial Results and Highlights 13427 7SEQUENOM Reports Second Quarter 2009 Financial Results and Highlights 13427 8SEQUENOM Reports Second Quarter 2009 Financial Results and Highlights 13427 9SEQUENOM Reports Second Quarter 2009 Financial Results and Highlights 13427 10Combo Treatment May Ease Depression After Stroke 53891 1Combo Treatment May Ease Depression After Stroke 53891 2[0] MEDRAD Demonstrates PACS Injection-Record Integration at RSNA 2009[0] Wound Management Technologies, Inc. Signs Agreement with Major Sales Representative Organization for Increased Marketing of CellerateRx(R); Third Quarter Sales Up[0] Cardium Files FDA 510(k) Application for U.S. Marketing Clearance of ExcellagenXL(TM) Topical Gel and ExcellagenFX(TM) Flowable Collagen Protein-Based Matrix for Diabetic, Pressure and Venous Ulcers and Other Dermal Wounds
...ONTO, Feb. 15 A seven-year, international,study p...es such as,acupuncture, neck manipulation and mass...ck pain than many current practices. Also included...exercises, education, neck,mobilization, low level...h as neck collars and ultrasound are not recommend...
...TH SAN FRANCISCO, Calif., Feb. 15 Cell,Genesys, I...an analysis,examining the potential association be...rostate cancer and increased patient survival in a...e refractory prostate cancer,(HRPC). More than 400...were,identified in the sera of the treated patient...
Other Medicine Technology:Seven-Year Neck Pain Study Sheds Light on Best Care 2Seven-Year Neck Pain Study Sheds Light on Best Care 3Cell Genesys Reports Association Between Immune Response and Patient Survival in Phase 2 Trial of GVAX Immunotherapy for Prostate Cancer 2Cell Genesys Reports Association Between Immune Response and Patient Survival in Phase 2 Trial of GVAX Immunotherapy for Prostate Cancer 3Cell Genesys Reports Association Between Immune Response and Patient Survival in Phase 2 Trial of GVAX Immunotherapy for Prostate Cancer 4Cell Genesys Reports Association Between Immune Response and Patient Survival in Phase 2 Trial of GVAX Immunotherapy for Prostate Cancer 5| Copyright © 2003-2009 Bio-Medicine. All rights reserved. ABOUT | CONTACT US | DISCLAIMER | PRIVACY POLICY | TERMS AND CONDITIONS |  |